Literature DB >> 32033760

Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease.

Julia Wattacheril1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) represents a global public health burden. NAFLD, while strongly associated with the metabolic syndrome, can occur independently from existing metabolic diseases. In addition to liver-related disease burden and mortality, significant extrahepatic disease outcomes coexist with NAFLD, including cardiovascular diseases, chronic kidney disease, and type 2 diabetes. Management of these comorbidities contributes to the overall public health burden of NAFLD. These extrahepatic manifestations require healthcare interventions that are vigilant in monitoring for progression of liver disease while simultaneously managing overall morbidity and mortality from other organ systems.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CKD; Cardiovascular; Diabetes; Extrahepatic; Fatty liver; Heart failure

Year:  2019        PMID: 32033760     DOI: 10.1016/j.gtc.2019.10.002

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  10 in total

1.  Inflammatory potential of diet and risk of nonalcoholic fatty liver disease: a prospective cohort study.

Authors:  Shunming Zhang; Ge Meng; Qing Zhang; Li Liu; Hongmei Wu; Yeqing Gu; Yawen Wang; Tingjing Zhang; Xuena Wang; Juanjuan Zhang; Shaomei Sun; Xing Wang; Ming Zhou; Qiyu Jia; Kun Song; Yaogang Wang; Lu Qi; Kaijun Niu
Journal:  Eur J Clin Nutr       Date:  2022-01-25       Impact factor: 4.884

2.  Key Genes Associated With Non-Alcoholic Fatty Liver Disease and Polycystic Ovary Syndrome.

Authors:  Yong Chen; Leikai Ma; Zhouling Ge; Yizhao Pan; Lubin Xie
Journal:  Front Mol Biosci       Date:  2022-05-25

Review 3.  Hypothyroidism-Induced Nonalcoholic Fatty Liver Disease (HIN): Mechanisms and Emerging Therapeutic Options.

Authors:  Daniela Maria Tanase; Evelina Maria Gosav; Ecaterina Neculae; Claudia Florida Costea; Manuela Ciocoiu; Loredana Liliana Hurjui; Claudia Cristina Tarniceriu; Mariana Floria
Journal:  Int J Mol Sci       Date:  2020-08-18       Impact factor: 5.923

4.  Liver fat content might be an appropriate measure for estimation of cardiovascular disease risk in non-alcoholic steatohepatitis patients.

Authors:  Raika Jamali; Saeed Pourhassan; Nastaran Maghbouli; Haleh Ashraf; Amir Ali Sohrabpour
Journal:  Med J Islam Repub Iran       Date:  2020-10-12

Review 5.  Nonalcoholic Fatty Liver Disease-Related Chronic Kidney Disease.

Authors:  Camelia Cojocariu; Ana-Maria Singeap; Irina Girleanu; Stefan Chiriac; Cristina M Muzica; Catalin Victor Sfarti; Tudor Cuciureanu; Laura Huiban; Carol Stanciu; Anca Trifan
Journal:  Can J Gastroenterol Hepatol       Date:  2020-12-29

6.  Comparison of Clinical Characteristics Between Obese and Non-Obese Patients with Nonalcoholic Fatty Liver Disease (NAFLD).

Authors:  Yifang Li; Yanzhen Chen; Xing Tian; Shanshan Zhang; Jian Jiao
Journal:  Diabetes Metab Syndr Obes       Date:  2021-05-06       Impact factor: 3.168

7.  The association between NAFLD and risk of chronic kidney disease: a cross-sectional study.

Authors:  Ying Cao; You Deng; Jingjing Wang; Hong Zhao; Jingyu Zhang; Wen Xie
Journal:  Ther Adv Chronic Dis       Date:  2021-11-09       Impact factor: 5.091

Review 8.  Combination Therapies for Nonalcoholic Fatty Liver Disease.

Authors:  Evangelia S Makri; Eleftheria Makri; Stergios A Polyzos
Journal:  J Pers Med       Date:  2022-07-18

9.  Association of serum creatinine with hepatic steatosis and fibrosis: a cross-sectional study.

Authors:  Juan Ma; Zhongcao Wei; Qian Wang; Xiaolan Lu; Zhihua Zhou; Ruohan Li; Qiuai Shu; Yixin Liu; Jinhai Wang; Na Liu; Haitao Shi
Journal:  BMC Gastroenterol       Date:  2022-07-27       Impact factor: 2.847

10.  Potential link between high FIB-4 score and chronic kidney disease in metabolically healthy men.

Authors:  Akihiro Kuma; Kosuke Mafune; Bungo Uchino; Yoko Ochiai; Tetsu Miyamoto; Akihiko Kato
Journal:  Sci Rep       Date:  2022-10-05       Impact factor: 4.996

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.